Survival-Toxicity Trade-off With T-DM1 in HER+ Breast Cancer Survival-Toxicity Trade-off With T-DM1 in HER+ Breast Cancer

Older patients with advanced HER2+ breast cancer do not experience a survival benefit with trastuzumab emtansine vs standard-of-care combination therapy, although toxicity is improved, a trial shows.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news